Results 171 to 180 of about 1,675 (195)

Peripheral lymphocyte subsets in the management of PTLD

Transplantation Proceedings, 2002
G L, Gupte, Sue V, Beath, P L, Amlot, C, James, D A, Kelly, P J, McKiernan, J, DeVille De Goyet   +6 more
openaire   +2 more sources

Organ Specific Issues of PTLD — Kidney

2010
Incidence of Posttransplant lymphoproliferative disorders (PTLD) in kidney transplant recipients is relatively low: 0.4% at 1 year, 1.2% at 5 years, and 1.6% after 10 years. Risk factors of PTLD in kidney transplant recipients are principally EBV seronegativity and high level of immunosuppression.
openaire   +1 more source

Uncommon Presentation of PTLD in the Esophagus

American Journal of Gastroenterology, 2007
Syed Abbas Fehmi, Sameer Saini, Wiliam Chey   +2 more
openaire   +1 more source

Systematic comparisons between Lyme disease and post-treatment Lyme disease syndrome in the U.S. with administrative claims data

EBioMedicine, 2023
Philip Strandwitz, Chirag J Patel, Mariaelena Caboni   +2 more
exaly  

Association of antiviral prophylaxis and rituximab use with posttransplant lymphoproliferative disorders (PTLDs): A nationwide cohort study

American Journal of Transplantation, 2021
Dionysios Neofytos, Oriol Manuel, Catrina Mugglin   +2 more
exaly  

Aktuelle integrative und supportive Therapieoptionen bei Post-Treatment Lyme Disease Syndrome (PTLDS) und Chronischer Lyme-Disease (CLD)

Zeitschrift Für Orthomolekulare Medizin
Burkhard Schutz, Thomas Welt
exaly   +2 more sources

Outcome of PTLD in renal and liver allograft recipients

Transplantation Proceedings, 2001
Gerstenkorn C, Jackson G, Di Franco F, Thomusch O, Talbot D   +4 more
openaire   +3 more sources

Immune Microenvironment in PTLDs: Comparison With Outcome and Other EBV+ Lymphoproliferative Disorders in Immunocompetenet and Immunodeficient Individuals

American Journal of Clinical Pathology, 2012
David Myerson
exaly  

Results of the Largest Study on Post-Transplant-Lymphoproliferations (PTLDs) of the Central Nervous System (CNS) in the Rituximab Era: A Surprising Overrepresentation of Kidney Transplantations, Key Importance of Methotrexate (Mtx), Cytarabine (AraC) and Radiotherapy (RX) for Long Term Survival and Low Impact of Rituximab (R)

Blood, 2008
Ralf Trappe, Ioannis Anagnostopoulos, Sylvain Choquet   +2 more
exaly  

Posttransplant Lymphoproliferative Disorder (PTLD)

2012
openaire   +1 more source